Skip to main content
SpringerLink
Log in

Under-prescribing of cardiovascular therapies for diabetes in primary care

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

To determine the extent to which cardiovascular therapies are prescribed in primary care for those with diabetes, compared with those without diabetes.

Methods

Population study of patients with and without diabetes identified using a national primary care prescribing database. All patients receiving a prescription for any diabetes therapy, including insulin and oral hypoglycaemic drugs, or diagnostic test kit for glucose (n=8523) and those receiving no such therapies (n=145,756) during a 1-year period (September 1999–August 2000) in the Eastern Regional Health Authority of Ireland were identified. In addition, a sub-set of patients receiving a nitrate prescription, a marker for ischaemic heart disease (IHD), were also identified (n=14,826). Odds ratios and 95% confidence intervals for prescribing of cardiovascular therapies between those with diabetes and those without, adjusted for age and gender, were calculated using logistic regression.

Results

The proportion of those (and 95% CES) with diabetes and IHD prescribed secondary preventative therapies was 37.3% (35.0, 39.6) for statins, 55.3% (53.0, 57.6) for angiotension converting enzyme inhibitors, 34.7% (32.5, 36.9) for β blockers, 73.3% (71.2, 75.4) for aspirin, 4.4% (3.4, 5.4) for angiotensin-II antagonists and 2.5% (1.8, 3.2) for fibrates. The adjusted odds ratios for prescribing in those with diabetes compared with those without are 1.44 (1.30, 1.61) for statins, 3.09 (2.79, 3.42) for angiotension converting enzyme inhibitors, 0.82 (0.74, 0.91) for β blockers, 1.23 (1.09, 1.38) for aspirin, 1.47 (1.13, 1.87) for angiotensin-II receptor blockers and 4.23 (2.88, 6.14) for lipid-lowering fibrates.

Conclusion

The greater rate of prescribing of cardiovascular therapies in those with diabetes relative to those without is not unexpected given the higher risk of coronary heart disease in those with diabetes. However, the proportion of patients with diabetes, particularly those with established IHD, prescribed cardiovascular therapies is considerably below that recommended in local and international guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lowel H, Koenig W, Engel S, Horman A, Keil U (2000) The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia 43:218–226

    Article  CAS  PubMed  Google Scholar 

  2. UK Prospective Diabetes Study Group (UKPDS) (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and the risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853

    PubMed  Google Scholar 

  3. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16:434–444

    CAS  PubMed  Google Scholar 

  4. Kannel W, D.McGee (1979) Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035–2038

    CAS  PubMed  Google Scholar 

  5. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H (1983) Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. BMJ 287:867–870

    CAS  PubMed  Google Scholar 

  6. Hypertension in Diabetes Study (HDS) (1993) Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 11:309–317

    PubMed  Google Scholar 

  7. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259

    PubMed  Google Scholar 

  8. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U et al (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359:1004–1010

    Article  CAS  PubMed  Google Scholar 

  9. Scandinavian Simvaststatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with CHD; the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389

    PubMed  Google Scholar 

  10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JD, Cole TG, Brown L et al (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1009

    Article  Google Scholar 

  11. Long-term Intervention with Pravastatin in Ischaemic Heart Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1357

    Google Scholar 

  12. Shephard J, Coble SM, Ford I, Isles CG, Lorimar AR, MacFarlane PW et al (1995) Prevention of coronary heart disease with prevastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301–1307

    CAS  PubMed  Google Scholar 

  13. Downs JR, Stein EA, Weis S, Clearfield M, Whitney E, Shapiro DR et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 279:1615–1622

    CAS  PubMed  Google Scholar 

  14. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:23–33

    Article  PubMed  Google Scholar 

  15. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al (1998) Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755–1762

    CAS  PubMed  Google Scholar 

  16. Department of Health and Children (1999) Building healthier hearts: the report of the Cardiovascular Health Strategy Group. Stationary Office, Dublin

    Google Scholar 

  17. Feely J (1999) The therapeutic gap—compliance with medication and guidelines. Atherosclerosis 147[Suppl 1]:S31–S37

  18. Irish College of General Practitioners Diabetes Task Group (2000) Guidelines for Diabetes Care in the Community. Dublin

  19. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K et al (1998) Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 19:1434–1503

    PubMed  Google Scholar 

  20. EUROASPIRE II Study Group (2001) Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22:554–572

    Article  PubMed  Google Scholar 

  21. Feely J, Chan R, McManus J, O'Shea B (1999) The influence of Hospital-based prescribers on prescribing in general practice. Pharmacoeconomics 16:175–181

    CAS  PubMed  Google Scholar 

  22. WHO (2001) Anatomical therapeutic chemical (ATC) classification index with defined daily doses (DDDs). Geneva

  23. McNally PG (1999) Epidemiology of heart disease in type 1 and 2 diabetes. In: McNally PG (ed) Diabetes and cardiovascular complications. Science, London

  24. Cannon P, Connell P, Stockley I, Garner S (1988) Prevalence of angina as assessed by a survey of prescriptions for nitrates. Lancet 1:979–981

    Google Scholar 

  25. Stata statistical software (1999) College Station, Texas

  26. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in patients with type 2 diabetes and in nondiabetic patients with and without prior myocardial infarction. New Engl J Med 339:229–234

    Article  CAS  PubMed  Google Scholar 

  27. American Diabetes Association (2001) Aspirin therapy in diabetes: position statement. Diabetes Care 24[Suppl 1]:1–4

    Google Scholar 

  28. Erkens JA, Stolk RP, Spolestra JA, Grobbee DE, Leufkens HGM, Klungel OH (2001) Cardiovascular drug use and Hospitilizations attributable to type 2 diabetes. Diabetes Care 24:1484–1432

    Google Scholar 

  29. UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713–720

    PubMed  Google Scholar 

  30. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL (1991) Why is diabetes mellitus a stronger risk factor for fatal ischaemic heart disease in women than men? The Rancho Bernado Study. JAMA 265:627–631

    CAS  PubMed  Google Scholar 

  31. Williams D, Feely J (2001) Co-prescribing with nitrate therapies shows neglect in secondary prevention. Br J Clin Pharmacol 51:379

    Google Scholar 

  32. Lawrence JM, Bennett P, Young A, Robinson AM (2001) Screening for diabetes in general practice: cross sectional population study. BMJ 323:548–551

    Article  CAS  PubMed  Google Scholar 

  33. Barry M, Heerey A (2002) Cost-effectiveness of statins for the secondary prevention of coronary heart disease in Ireland. Ir Med J 95:133–135

    PubMed  Google Scholar 

  34. IDF(Europe) (1999) Desktop guide to type 2 diabetes mellitus. Diabetic Med 16:730

    Google Scholar 

  35. IDF(Europe) (1999) Desktop guide to type 1 diabetes mellitus. Diabetes Nutr Metab 12:345–378

    PubMed  Google Scholar 

Download references

Acknowledgements

We thank the GMS (Payments) Board for supplying the prescription data on which this study was based and Ms Adrienne Heerey for data management.

Author information

Authors and Affiliations

  1. Department of Therapeutics and Pharmacology, Trinity Centre for Health Sciences, St James's Hospital, Dublin 8, Ireland

    K. E. Bennett & J. Feely

  2. Department of Clinical Pharmacology, Aberdeen Royal Infirmary, Ward 12, AB 25 2ZN Aberdeen, Ireland

    D. Williams

  3. National Medicines Information Centre/Centre for Pharmacoeconomics, St James's Hospital, Dublin 8, Ireland

    K. E. Bennett

Authors
  1. K. E. Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Feely
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. E. Bennett.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bennett, K.E., Williams, D. & Feely, J. Under-prescribing of cardiovascular therapies for diabetes in primary care. Eur J Clin Pharmacol 58, 835–841 (2003). https://doi.org/10.1007/s00228-002-0542-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-002-0542-6

Keywords

Search

Navigation